Abstract:Rationale: Lung cancer is the leading cause of cancer-associated deaths all over the world. Although the prognosis of lung cancer has improved over the past decade due to progression in surgical techniques and systematic treatments, the patients with advanced disease still suffer poor survival. There are no standard treatment strategies for patients who have failed to respond to at least 2 lines of chemotherapy in non-small cell lung cancer (NSCLC). Apatinib, one of the latest small-molecule oral anti-angiogenesis targeted agents developed first in China, has shown remarkable anti-tumor efficacy in a variety of solid tumor types. Patient concerns: A 72-year-old woman underwent radical resection of the left lung cancer in July 2011, but was found a recurrence of cancer after 2 years. Diagnoses: The histopathological examination of the resected specimen identified the lesion as lung adenocarcinoma. Interventions: She received gemcitabine and carboplatin regimen as adjuvant chemotherapy for 4 cycles following the surgery in August 2011. After the tumor relapsed, she received multiple lines of chemotherapy including paclitaxel, cisplatin, docetaxel, and gemcitabine from July 2013, but still suffered progressive disease in February 2017. Then apatinib alone was used to defend against the tumor at a dose of 250 mg/d orally till December 2017. Outcomes: The efficacy was assessed as partial response 1 month later in March 2017. And the use of apatinib was continued till the patient died of tumor progression, achieving a progression-free survival for 10 months. During the treatment with apatinib, the patient experienced hypertension of grade 1, which was well-tolerated and manageable. Lessons: Apatinib might be efficient and well-tolerated for patients with advanced NSCLC who have failed to respond to multi-line treatments, even at a low dose.

Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.

A Marked Response to Icotinib in a Patient with Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation: A Case Report.

Low Dose of Apatinib in Treating Chemotherapy and EGFR-TKI Refractory Non-Small Cell Lung Cancer A Case Report

Response to Pemetrexed Rechallenge after Acquired Resistance of EGFR-TKI in a Patient with Advanced NSCLC.

P3.01-104 EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report

EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report

Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review

Case report: A lung squamous cell carcinoma patient with a rare EGFR G719X mutation and high PD-L1 expression showed a good response to anti-PD1 therapy

Remarkable response to third-generation EGFR-TKI plus crizotinib in a patient with pulmonary adenocarcinoma harboring EGFR and ROS1 co-mutation: a case report

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Conventional Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report.

Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report

Case Report: Favorable Efficacy of Combined Afatinib and Anlotinib Treatment in a Lung Adenocarcinoma Patient Harboring Uncommon EGFR L858M/L861R Mutations

EGFR L747P Mutation in One Lung Adenocarcinoma Patient Responded to Afatinib Treatment: a Case Report

Role of Allogeneic Natural Killer T Cells in the Treatment of a Patient with Gefitinib-Sensitive Lung Adenocarcinoma.

Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report

Case Report: the Effective Treatment of Patients in Advanced No-Small Cell Lung Cancer Patients with EGFR G719X/S768I/L861Q and Acquired MET Amplification: A Case Series and Literature Review

Long-term Survival of a Non-Small Cell Lung Cancer Patient with EGFR-mutated Brain Metastases: a Case Report.

Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report

EGFR-tyrosine Kinase Inhibitor Treatment in a Patient with Advanced Non-Small Cell Lung Cancer and Concurrent Exon 19 and 21 EGFR Mutations: A Case Report and Review of the Literature.

Combination therapy with afatinib and bevacizumab in an <i>EGFR</i>-mutated non-small cell lung cancer patient with acquired ERBB2 amplification A case report